Covered recipient · General Payments record
SARA KOENIG
Allopathic & Osteopathic Physicians Preventive Medicine Addiction Medicine
General Payments · PY2019–2024
$1,224.06
- Reported across 58 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $430.69 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $135.68 | 7 |
| Axsome Therapeutics, Inc. | $122.76 | 2 |
| Braeburn Inc. | $67.36 | 3 |
| Alkermes, Inc. | $47.43 | 2 |
| IDORSIA PHARMACEUTICALS US INC | $31.91 | 2 |
| Indivior Inc. | $25.55 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $14.76 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104092438 | CMS |
| ABBVIE INC. | $29.31 | 02/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104092440 | CMS |
| ABBVIE INC. | $21.50 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104092442 | CMS |
| ABBVIE INC. | $19.35 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104092444 | CMS |
| ABBVIE INC. | $6.12 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104092446 | CMS |
| ABBVIE INC. | $17.59 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104092448 | CMS |
| ABBVIE INC. | $27.05 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104092450 | CMS |
| Alkermes, Inc. | $24.95 | 03/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120534207 | CMS |
| Alkermes, Inc. | $22.48 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120534209 | CMS |
| Axsome Therapeutics, Inc. | $23.49 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148318978 | CMS |
| Axsome Therapeutics, Inc. | $99.27 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148318980 | CMS |
| Braeburn Inc. | $20.33 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125607115 | CMS |
| Braeburn Inc. | $24.40 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125607117 | CMS |
| Braeburn Inc. | $22.63 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125607119 | CMS |
| IDORSIA PHARMACEUTICALS US INC | $16.30 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146766354 | CMS |
| IDORSIA PHARMACEUTICALS US INC | $15.61 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146772756 | CMS |
| Indivior Inc. | $25.55 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144531558 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.